Combination therapy of dyslipidemia in non-insulin-dependent diabetes mellitus and the metabolic syndrome.
Non-insulin-dependent diabetes mellitus (NIDDM) and the metabolic syndrome separately and additively increase the risk for atherosclerotic cardiovascular disease. Considering the high cardiovascular risk associated with NIDDM and the metabolic syndrome, aggressive therapy of dyslipidemia with tailored combination therapy should be considered given informed consent and discussion of risks. In addition to statins, niacin, and fibrates, therapies shown to decrease the risk for atherosclerotic cardiovascular disease include omega-3 fatty acids, diet, exercise, and optimal blood pressure control with thiazides and blockers of the renin-angiotensin system. These therapies should also be considered to reduce the high cardiovascular risk associated with NIDDM and the metabolic syndrome.
Rembold
Christopher M
CM
Box 801395, Cardiovascular Division, Departments of Internal Medicine and Physiology, University of Virginia Health System, Charlottesville, VA 22908-1395, USA. crembold@virginia.edu.
D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D024821:Metabolic Syndrome / Q000150:complications* / Q000188:drug therapy*
D000960:Hypolipidemic Agents